Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound 2z is a membrane-active N,N'-diarylurea derivative developed as an antibacterial agent targeting multidrug-resistant *Staphylococcus aureus* (MRSA) infections [1]. Synthesized as part of a library of 65 diarylurea derivatives, compound 2z was identified as the most potent candidate in a *Galleria mellonella* infection model [1]. It exhibits strong bactericidal activity against both planktonic and persister cells, disrupts established biofilms, and has demonstrated significant therapeutic efficacy in a murine peritonitis model [1]. Compound 2z exerts its antibacterial effects by disrupting the bacterial cell membrane (affecting membrane permeability, depolarization, and fluidity) without inducing resistance even after serial passages [1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound 2z.